AHA presentation demonstrating the complementary value of the Bodyport Congestion Index and PA pressure monitoring in heart failure patients

Bodyport develops remote monitoring technologies for patients with fluid management-related health conditions. The FDA-cleared Bodyport Cardiac Scale measures weight, peripheral impedance, pulse rate, and balance through a simple daily measurement. Bodyport’s clinician-facing software combines longitudinal data into the Congestion Index, a clinical decision support tool that helps healthcare professionals identify and evaluate changes associated with worsening congestion.Based in San Francisco, the company is backed by top-tier investors including Boehringer Ingelheim Venture Fund, Terumo Medical, Initialized Capital, Playground Global, Rock Health, and Y Combinator. For more information, visit bodyport.com and follow the company on LinkedIn and Twitter.